Skip to main content

Site notifications

MOUNJARO (Eli Lilly Australia Pty Ltd)

Product name
MOUNJARO
Date registered
Evaluation commenced
Decision date
Approval time
160 (255 working days)
Active ingredients
tirzepatide
Registration type
EOI
Indication

MOUNJARO is now also indicated for the treatment of moderate to severe obstructive sleep apnoea in adults with obesity.